66th Annual Meeting of the Japanese Society of Neurology
Advanced Search

Session Details

Symposium

[S-42]Symposium 42　Development of new therapeutics in immune-mediated neuropathies: Progress of basic research and clinical trials

Sat. May 24, 2025 8:00 AM - 9:30 AM JST
Sat. May 24, 2025 11:00 PM - 12:30 AM UTC
第02会場(大阪国際会議場5F 小ホール)
Chairs: Kenichi Kaida（Dept. of Neurology, Saitama Medical Center, Saitama Medical University, Japan）, Motoi Kuwahara（Department od Neurology, Kindai University Faculty of Medicine, Japan）
The development of new treatments for immune-mediated neuropathies is progressing rapidly. The aim of this symposium is to introduce the current status of clinical trials of new therapeutic drugs, as well as the current state of basic research that forms the basis for the development of new therapeutic drugs, and to indicate the direction of treatment development.

[S-42-1]Advancing Translational Research in Guillain-Barré syndrome: Current Treatment and Clinical Trials

Zhahirul Islam1, Mantaka Rahman1, Nowshin Papri1, Imran Hasan1, Israt Jahan1, Shoma Hayat1, Quazi Deen. Mohammad2 (1.Gut-Brain Axis, icddr,b, Dhaka, Bangladesh, 2.National Institute of Neurosciences and Hospital, Dhaka, Bangladesh, Bangladesh)
Dr. Zhahirul Islam is a Senior Scientist and Head of the Gut-Brain Axis Laboratory at icddr,b. He achieved his Ph.D. from Erasmus University Medical Center, The Netherlands, in collaboration with icddr,b, focusing on Campylobacter infection and Guillain-Barré syndrome (GBS). In 2015-16, he was selected as a Postdoctoral Fellow in the prestigious Global Health Equity Scholars (GHES) program, supported by the NIH, USA, in collaboration with Stanford University, USA and icddr,b. In 2019, Dr. Islam received the Emerging Global Leader Award from the NIH, USA. As a pioneer in GBS research in low- and middle-income countries (LMICs), he has served as the country coordinator (Bangladesh, 2012-) and a steering committee member (2023-) for the International GBS Outcome Study (IGOS). Dr. Islam’s research interests encompass molecular epidemiology, computational biology, cellular immunity, metagenomics, and novel therapeutics for GBS and other autoimmune diseases. His team has developed a cost-effective treatment, Small Volume Plasma Exchange (SVPE), for GBS patients in LMICs. Currently, he is conducting a phase 2/3 clinical trial on a novel monoclonal antibody (C1q inhibitor) for GBS. Additionally, he leads an NIH-funded project to identify biomarkers, nutritional factors, and microbial strain-level differences to predict IVIg treatment response in GBS patients in LMICs.

[S-42-2]Therapeutic strategy and future outlooks for CIDP

Tomoko Okamoto (Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan)
Tomoko Okamoto is the Deputy Director of the Department of Neurology at National Center Hospital, National Center of Neurology and Psychiatry.
Specialized field is Neurology, Neuroimmunology, and Neurophysiology.
Completed the Graduate School of Medicine, Shiga University of Medicine in 1995, and obtained a Ph.D.

Career
1989-1997; Third Department of Medicine, Shiga University of Medical Science, Shiga　
1997-2001; Department of Physiology, University of Munich, Germany
2001-2006; Department of Neurology, Utano National Hospital, Kyoto
2006～Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo

Activities of Academic Societies
Delegates of the Japanese Society of Neurology
Councilor of the Japanese Peripheral Nerve Society
Director and Councilor of the Japanese Society for Neuroimmunology

[S-42-3]Clinical trials and new treatment strategy in anti-MAG neuropathy

Masanori Nakajima1,3, Ken-ichi Kaida2 (1.Internal Medicine, Morioka Health Cooperative Association, Kawakubo Hospital, Japan, 2.Department of Neurology, Saitama Medical Center, Saitama Medical University, Japan, 3.Department of Neurology, Kyorin University School of Medicine, Japan)
March 2010: Graduated from Saitama Medical University Faculty of Medicine
April 2010: Initial training started in Health Cooperative Saitama, Saitama Cooperative Hospital
March 2012: Initial training completed in Health Cooperative Saitama, Saitama Cooperative Hospital
April 2012: General Internal Medicine in Health Cooperative Saitama, Saitama Cooperative Hospital
April 2013: Internal Medicine in Morioka Health Cooperative Association, Kawakubo Hospital
April 2014: Resident in Department of Neurology, Kyorin University Hospital
April 2015: Medical staff in Department of Neurology, Kyorin University Hospital
April 2020: Assistant Professor (fixed term) in Department of Neurology, Kyorin University School of Medicine
March 2023: Finished Kyorin University Graduate School of Medicine (Department of Internal Medicine and Neurology)
April 2023: Internal Medicine in Morioka Health Cooperative Association, Kawakubo Hospital

[S-42-4]Current therapeutic strategy and clinical trials in neuropathy of ANCA-associated vasculitis

Ryota Sato (Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Japan)
EDUCATION
2005-2011 Yamaguchi University Faculty of Medicine and Health Sciences
2017-2023 Yamaguchi University Graduate School of Medicine
WORK EXPERIENCE
Junior resident
Apr 2011- Mar 2013 Yamaguchi Prefecture Grand Medical Center
Neurology Trainee
Apr 2013- Mar 2014 Yamaguchi University Graduate School of Medicene
Apr 2014- Mar 2015 Yamaguchi Prefecture Grand Medical Center
Apr 2015- Mar 2017 National Hospital Organization Kanmon Medical Center
Apr 2017- present Yamaguchi University Graduate School of Medicene
QUALIFICATIONS AND MEMBERSHIPS
Qualified Neurologist (The Japanese Society of Neurology)
The Japanese Society of Internal Medicine - member
The Japanese Society of Neurology - member
The Japanese Society of Neuropathology - member
Japanese Peripheral Nerve Society - member
Japan Society for Dementia Research - member
The Japan Stroke Society - member
Peripheral Nerve Society - member
Back to Category List